PUBLISHER: IMARC | PRODUCT CODE: 1518752
PUBLISHER: IMARC | PRODUCT CODE: 1518752
The Japan diabetes market size reached US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032.
Diabetes refers to a chronic disease in which the ability of a human body to produce and respond to insulin hormone becomes impaired. This results in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood. In Japan, a large section of the population is over 60 years, an age when type-2 diabetes becomes more prevalent. Moreover, as the Japanese diet consists of a significant portion of refined carbohydrates, like white rice and noodles, it puts the population at a higher risk of developing and aggravating diabetes.
With the growing influence of western cuisines, increasing working hours and declining domestic agricultural production, consumers are now relying on processed food products and fast-food like burger, taco, hotdog and pizza. As these food products are high in carbohydrates, sodium and preservatives, their rising consumption has increased the cases of diabetes in the country. The other factors that are contributing to the increasing cases of diabetes include growing obese population and sedentary lifestyles. However, to minimize the prevalence of diabetes in the country, the Government of Japan is undertaking several initiatives. For instance, it is offering health insurance to both the citizens and non-citizens residing for more than a year in Japan through their universal health care system.
IMARC Group provides an analysis of the key trends in each segment of the Japan diabetes market report, along with forecasts for the period 2024-2032. Our report has categorized the market based on segment.
Oral Antidiabetics
Insulin
Currently, insulin represents the dominant segment, accounting for the majority of the total market share. Insulin in Japan is usually taken through pens, pumps, syringes and jet injectors as they offer convenience to the patients. Increasing diagnostic rates and awareness among patients are enabling them to incorporate insulin therapy for treating diabetes.
The competitive landscape of the market has been analyzed in the report with detailed profiles of key players operative in the industry.